Merrimack

Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery, design, and development of therapies for treating diseases in the fields of autoimmune disorders and cancer. It has developed MM-093, a human alpha-fetoprotein, for the treatment of patients with rheumatoid arthritis and psoriasis; MM-121, a human monoclonal antibody designed to block ErbB3 receptor signaling, serves as both an antibody and therapeutic agent. Merrimack Pharmaceuticals, Inc. was formerly known as Atlantic BioPharmaceuticals, Inc.